Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
02:20pm, Thursday, 19'th Jan 2023 The Motley Fool
The Food and Drug Administration authorized Leqembi under an accelerated approval pathway this month.
If You Invested $25,000 in Biogen in 2018, This Is How Much You Would Have Today
10:25am, Thursday, 19'th Jan 2023 The Motley Fool
The stock hasn't been a great investment in recent years, but there's hope for a brighter future.
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
09:20am, Thursday, 19'th Jan 2023
The Food and Drug Administration authorized Leqembi under an accelerated approval pathway this month.
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich
10:55am, Tuesday, 17'th Jan 2023 The Motley Fool
The fountain of youth might not be a myth in the future.
Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan
05:33pm, Monday, 16'th Jan 2023 Zacks Investment Research
Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early Alzheimer's disease in Japan.
Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan
02:18pm, Monday, 16'th Jan 2023
Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early Alzheimer's disease in Japan.
Prothena (PRTA) Stock Gains 88.5% in 6 Months: What Lies Ahead?
07:47pm, Friday, 13'th Jan 2023 Zacks Investment Research
Prothena (PRTA) surges 88% in the last six months as investors are optimistic on its promising Alzheimer???s Disease pipeline.
Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know
11:00pm, Thursday, 12'th Jan 2023 Zacks Investment Research
Biogen Inc. (BIIB) closed at $288.08 in the latest trading session, marking a +1.07% move from the prior day.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
11:20am, Thursday, 12'th Jan 2023 Zacks Investment Research
Sector ETF report for XBI
Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe
02:38pm, Wednesday, 11'th Jan 2023 Zacks Investment Research
Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early Alzheimer's disease in Europe.
Ranking The 10 Largest Biotechs By Pipeline
12:34pm, Wednesday, 11'th Jan 2023
The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment
Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe
11:17am, Wednesday, 11'th Jan 2023
Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early Alzheimer's disease in Europe.
1 Hot Growth Stock to Buy Now, and 1 to Avoid
10:30am, Wednesday, 11'th Jan 2023 The Motley Fool
One company is gearing up for further growth while the other stumbles over itself.
1 Hot Growth Stock to Buy Now, and 1 to Avoid
05:30am, Wednesday, 11'th Jan 2023
One company is gearing up for further growth while the other stumbles over itself.
Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?
10:55am, Tuesday, 10'th Jan 2023 The Motley Fool
There's more to the story with Biogen after receiving good news for Leqembi.
